Karen Noblett's Insider Trades & SAST Disclosures
Karen Noblett's most recent trade in Axonics Inc was a trade of 34,428 Common Stock done at an average price of $71 . Disclosure was reported to the exchange on Nov. 15, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Karen Noblett.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Axonics Inc | Karen Noblett | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 71.00 per share. | 15 Nov 2024 | 34,428 | 0 (0%) | 0% | 71 | 2,444,388 | Common Stock |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Nov 2024 | 11,998 | 0 | - | - | Stock Option (Right to Buy) | |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Nov 2024 | 7,500 | 0 | - | - | Performance-Based Restricted Stock Units | |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Nov 2024 | 6,348 | 0 | - | - | Stock Options (Right to buy) | |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Nov 2024 | 2,963 | 0 | - | - | Stock Option (Right to Buy) | |
| Axonics Inc | Noblett Karen | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 27,500 | 45,716 (0%) | 0% | 0 | Common Stock | |
| Axonics Inc | Noblett Karen | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 15,000 | 0 | - | - | Performance-Based Restricted Stock Units | |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 67.74 per share. | 31 Jan 2024 | 11,288 | 34,428 (0%) | 0% | 67.7 | 764,603 | Common Stock |
| Axonics Inc | Noblett Karen | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 6,500 | 0 | - | - | Performance-Based Restricted Stock Units | |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 69.00 per share. | 08 Jan 2024 | 15,999 | 18,216 (0%) | 0% | 69.0 | 1,103,961 | Common Stock |
| Axonics Inc | Noblett Karen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 63.28 per share. | 26 Dec 2023 | 7,051 | 34,215 (0%) | 0% | 63.3 | 446,177 | Common Stock |
| Axonics Inc | Noblett Karen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 63.00 per share. | 26 Dec 2023 | 949 | 41,266 (0%) | 0% | 63 | 59,787 | Common Stock |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 15,000 | 15,000 | - | - | Performance-Based Restricted Stock Units | |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 10,250 | 46,849 (0%) | 0% | 0 | Common Stock | |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 6,000 | 0 | - | - | Performance-Based Restricted Stock Units | |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 5,000 | 36,599 (0%) | 0% | 0 | Common Stock | |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 5,000 | 5,000 | - | - | Performance-Based Restricted Stock Units | |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 4,250 | 0 | - | - | Performance-Based Restricted Stock Units | |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 61.17 per share. | 31 Jan 2023 | 2,167 | 44,682 (0%) | 0% | 61.2 | 132,554 | Common Stock |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 61.12 per share. | 31 Jan 2023 | 1,536 | 43,146 (0%) | 0% | 61.1 | 93,883 | Common Stock |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 61.02 per share. | 31 Jan 2023 | 795 | 42,215 (0%) | 0% | 61.0 | 48,508 | Common Stock |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.43 per share. | 31 Jan 2023 | 136 | 43,010 (0%) | 0% | 60.4 | 8,219 | Common Stock |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 78.16 per share. | 12 Sep 2022 | 32,483 | 31,599 (0%) | 0% | 78.2 | 2,538,800 | Common Stock |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.19 per share. | 12 Sep 2022 | 18,519 | 50,118 (0%) | 0% | 14.2 | 262,785 | Common Stock |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2022 | 18,519 | 2,963 | - | - | Stock Option (Right to Buy) | |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2022 | 13,964 | 6,348 | - | - | Stock Options (Right to buy) | |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.82 per share. | 12 Sep 2022 | 13,964 | 64,082 (0%) | 0% | 25.8 | 360,550 | Common Stock |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 57.23 per share. | 18 Mar 2022 | 13,531 | 42,053 (0%) | 0% | 57.2 | 774,359 | Common Stock |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 19,463 | 62,266 (0%) | 0% | 0 | Common Stock | |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 14,130 | 0 | - | - | Performance-Based Restricted Stock Units | |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 48.21 per share. | 31 Jan 2022 | 6,343 | 55,923 (0%) | 0% | 48.2 | 305,798 | Common Stock |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 5,350 | 42,803 (0%) | 0% | 0 | Common Stock | |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 5,333 | 0 | - | - | Performance-Based Restricted Stock Units | |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 4,250 | 4,250 | - | - | Performance-Based Restricted Stock Units | |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 3,250 | 3,250 | - | - | Performance-Based Restricted Stock Units | |
| Axonics Inc | Karen Noblett | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 49.04 per share. | 31 Jan 2022 | 339 | 55,584 (0%) | 0% | 49.0 | 16,623 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges